Maneesha Sharma1, Lokesh Kumar Bhatt2. 1. Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. 2. Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. lokesh.bhatt@bncp.ac.in.
Abstract
PURPOSE OF REVIEW: Heart failure is a global epidemic that affects at least 26 million individuals globally and is becoming more prevalent. Despite advances in treatment strategies, survival and symptom management in individuals with heart failure remain exceptionally low. This review discusses emerging targets for the treatment of heart failure. RECENT FINDINGS: Recently, a number of targets are being investigated as prospective treatment possibilities for heart failure. These include targets like Runx1 transcription factor (RUNX1), milk fact globule-EFG factor 8 (MFGE8) protein and enzymes such as neuraminidase 1 (NEU1), G protein-coupled receptor kinase 5 (GRK5), G protein-coupled oestrogen receptor 1 (GPER1), urotensin-II receptor (UTR), cluster of differentiation 47 (CD47) and relaxin receptor 1 (RXFP1). On a worldwide level, heart failure is a developing epidemic with substantial morbidity and death. The number of individuals diagnosed with chronic heart failure is rising, and it is anticipated to surge by 46% by 2030. Appropriate heart failure treatment can have the greatest influence on prolonging patients' lives in the coming year. Targets discussed in this review may provide new therapeutic approaches for the treatment of heart failure.
PURPOSE OF REVIEW: Heart failure is a global epidemic that affects at least 26 million individuals globally and is becoming more prevalent. Despite advances in treatment strategies, survival and symptom management in individuals with heart failure remain exceptionally low. This review discusses emerging targets for the treatment of heart failure. RECENT FINDINGS: Recently, a number of targets are being investigated as prospective treatment possibilities for heart failure. These include targets like Runx1 transcription factor (RUNX1), milk fact globule-EFG factor 8 (MFGE8) protein and enzymes such as neuraminidase 1 (NEU1), G protein-coupled receptor kinase 5 (GRK5), G protein-coupled oestrogen receptor 1 (GPER1), urotensin-II receptor (UTR), cluster of differentiation 47 (CD47) and relaxin receptor 1 (RXFP1). On a worldwide level, heart failure is a developing epidemic with substantial morbidity and death. The number of individuals diagnosed with chronic heart failure is rising, and it is anticipated to surge by 46% by 2030. Appropriate heart failure treatment can have the greatest influence on prolonging patients' lives in the coming year. Targets discussed in this review may provide new therapeutic approaches for the treatment of heart failure.
Authors: Charlotte S McCarroll; Weihong He; Kirsty Foote; Ashley Bradley; Karen Mcglynn; Francesca Vidler; Colin Nixon; Katrin Nather; Caroline Fattah; Alexandra Riddell; Peter Bowman; Elspeth B Elliott; Margaret Bell; Catherine Hawksby; Scott M MacKenzie; Liam J Morrison; Anne Terry; Karen Blyth; Godfrey L Smith; Martin W McBride; Thomas Kubin; Thomas Braun; Stuart A Nicklin; Ewan R Cameron; Christopher M Loughrey Journal: Circulation Date: 2017-10-13 Impact factor: 29.690
Authors: Alexandra Riddell; Martin McBride; Thomas Braun; Stuart A Nicklin; Ewan Cameron; Christopher M Loughrey; Tamara P Martin Journal: Cardiovasc Res Date: 2020-07-01 Impact factor: 10.787